- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S1473
| Related Targets | Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase Vitamin Carbohydrate Metabolism Mitochondrial Metabolism Drug Metabolite |
|---|---|
| Other PPAR Inhibitors | T0070907 GW9662 GW6471 WY-14643 (Pirinixic Acid) GSK3787 GW0742 AZ6102 Astaxanthin Eupatilin GSK0660 |
|
In vitro |
DMSO
: 91 mg/mL
(200.66 mM)
Ethanol : 22 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 453.50 | Formula | C21H18F3NO3S2 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 317318-70-0 | Download SDF | Storage of Stock Solutions |
|
|
| Features |
A selective PPARδ agonist compared with a synthetic LXRα agonist GW3965.
|
|---|---|
| Targets/IC50/Ki |
PPARδ
1.1 nM(EC50)
|
| In vitro |
GW501516 is demonstrated to be 1000-fold more selective in comparison to existing subtypes. This compound increases expression of the reverse cholesterol transporter ATP-binding cassette A1 and induces apolipoprotein A1-specific cholesterol efflux In macrophages, fibroblasts, and intestinal cells. It can regulate expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Additionally, this chemical is shown to block insulin resistance and fatty acid-induced nuclear factor-κB activation. It reduces the IFNγ-induced up-regulation of TNFα and inducible NO synthase, and showed anti-inflammatory activity.
|
| In vivo |
GW501516 dramatically increases serum high density lipoprotein cholesterol while lowering the levels of small-dense low density lipoprotein, fasting triglycerides, and fasting insulin when dosed to insulin-resistant middle-aged obese rhesus monkeys. This compound induces fatty acid β-oxidation in L6 myotubes and in mouse skeletal muscles. Its treatment to mice fed a high-fat diet ameliorates diet-induced obesity as well as insulin resistance. This chemical also dramatically improves diabetes, as demonstrated by the decrease in plasma glucose and blood insulin levels in genetically obese ob/ob mice.
|
References |
|
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.